» Articles » PMID: 32026656

Risk Factors for Early Death Among Ovarian Cancer Patients: a Nationwide Cohort Study

Overview
Journal J Gynecol Oncol
Date 2020 Feb 7
PMID 32026656
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To characterize ovarian cancer patients who die within 6 months of diagnosis and to identify prognostic factors for these early deaths.

Methods: A nationwide cohort study covering ovarian cancer in Denmark in 2005-2016. Tumor and patient characteristics including comorbidity and socioeconomic factors were obtained from the comprehensive Danish national registers.

Results: A total of 5,570 patients were included in the study. Three months after ovarian cancer diagnosis 456 (8.2%) had died and 664 (11.9%) died within 6 months of diagnosis. Adjusted for age and comorbidity, patients who died early were admitted to hospital significantly more often in a 6-month period before the diagnosis (odds ratio [OR]=1.61 [1.29-2.00], and OR=1.47 [1.21-1.78]), for patients who died within 3 and 6 months respectively). Low educational level (OR=2.11), low income (OR=2.50) and singlehood (OR=1.90) were factors significantly associated with higher risk of early death. The discriminative ability of risk factors in identifying early death was assessed by cross-validated area under the receiver operating characteristic curve (AUC). The AUC was found to be 0.91 (0.88-0.93) and 0.90 (0.87-0.92) for death within 3 and 6 months, respectively.

Conclusions: Despite several admissions to hospital, the ovarian cancer diagnosis is delayed for a subgroup of patients, who end up dying early, probably due to physical deterioration in the ineffective waiting time. Up to 90% of high-risk patients might be identified significantly earlier to improve the prognosis. The admittance of the patients having risk symptoms should include fast track investigation for ovarian cancer.

Citing Articles

Identifying risk factors for cancer-specific early death in patients with advanced endometrial cancer: A preliminary predictive model based on SEER data.

Yang J, Tian Q, Li G, Liu Q, Tang Y, Jiang D PLoS One. 2025; 20(2):e0318632.

PMID: 39937848 PMC: 11819511. DOI: 10.1371/journal.pone.0318632.


Nomogram for predicting the early death of patients with stage IV ovarian cancer: a retrospective analysis of the SEER database.

Chen P, Zheng S, Zhang L Transl Cancer Res. 2024; 13(11):5845-5855.

PMID: 39697763 PMC: 11651799. DOI: 10.21037/tcr-24-625.


Identifying Factors Contributing to Delayed Diagnosis of Ovarian Cancer: A Comprehensive Analysis.

Hong K, Liu Y, Yin H, Huang K, Pu X, Zhu Z Int J Womens Health. 2024; 16:1463-1473.

PMID: 39257719 PMC: 11383536. DOI: 10.2147/IJWH.S473381.


Aryl Hydrocarbon Receptor Promotes Cell Growth, Stemness Like Characteristics, and Metastasis in Human Ovarian Cancer via Activation of PI3K/Akt, β-Catenin, and Epithelial to Mesenchymal Transition Pathways.

Therachiyil L, Krishnankutty R, Ahmad F, Mateo J, Uddin S, Korashy H Int J Mol Sci. 2022; 23(12).

PMID: 35742838 PMC: 9223661. DOI: 10.3390/ijms23126395.


Nomogram for predicting postoperative cancer-specific early death in patients with epithelial ovarian cancer based on the SEER database: a large cohort study.

Zhang T, Zhu L Arch Gynecol Obstet. 2021; 305(6):1535-1549.

PMID: 34841445 PMC: 9166879. DOI: 10.1007/s00404-021-06342-x.

References
1.
Maringe C, Walters S, Butler J, Coleman M, Hacker N, Hanna L . Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership. Gynecol Oncol. 2012; 127(1):75-82. DOI: 10.1016/j.ygyno.2012.06.033. View

2.
Fago-Olsen C, Hogdall C, Kehlet H, Christensen I, Ottesen B . Centralized treatment of advanced stages of ovarian cancer improves survival: a nationwide Danish survey. Acta Obstet Gynecol Scand. 2011; 90(3):273-9. DOI: 10.1111/j.1600-0412.2010.01043.x. View

3.
Berglund A, Wigertz A, Adolfsson J, Ahlgren J, Fornander T, Warnberg F . Impact of comorbidity on management and mortality in women diagnosed with breast cancer. Breast Cancer Res Treat. 2012; 135(1):281-9. DOI: 10.1007/s10549-012-2176-4. View

4.
Stairmand J, Signal L, Sarfati D, Jackson C, Batten L, Holdaway M . Consideration of comorbidity in treatment decision making in multidisciplinary cancer team meetings: a systematic review. Ann Oncol. 2015; 26(7):1325-32. DOI: 10.1093/annonc/mdv025. View

5.
Jorgensen T, Teiblum S, Paludan M, Ostergaard Poulsen L, Jorgensen A, Bruun K . Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients. Gynecol Oncol. 2012; 127(2):367-74. DOI: 10.1016/j.ygyno.2012.07.001. View